Mira Pharmaceuticals to Acquire BioGenetics, Inc.
Ticker: MIRA · Form: 8-K · Filed: Jul 24, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Jul 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, biotechnology, merger
TL;DR
Mira Pharma buying BioGenetics to boost pipeline. Deal expected Q3.
AI Summary
Mira Pharmaceuticals, Inc. announced on July 24, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of BioGenetics, Inc. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions. This strategic move aims to expand Mira Pharmaceuticals' product pipeline and market reach.
Why It Matters
This acquisition could significantly expand Mira Pharmaceuticals' product offerings and market presence in the biotechnology sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and potential overvaluation, which could impact Mira Pharmaceuticals' financial performance.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- BioGenetics, Inc. (company) — Acquisition Target
- July 24, 2024 (date) — Announcement Date
- Third Quarter of 2024 (date) — Expected Closing Period
FAQ
What is the primary purpose of the acquisition of BioGenetics, Inc. by Mira Pharmaceuticals, Inc.?
The acquisition is intended to expand Mira Pharmaceuticals' product pipeline and market reach.
When is the acquisition of BioGenetics, Inc. expected to close?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the closing of the BioGenetics, Inc. acquisition?
The closing is subject to customary closing conditions.
What is Mira Pharmaceuticals, Inc.'s principal executive office address?
Mira Pharmaceuticals, Inc.'s principal executive office is located at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
What was Mira Pharmaceuticals, Inc.'s former company name?
Mira Pharmaceuticals, Inc.'s former company name was Mira1a Therapeutics, Inc.
Filing Stats: 956 words · 4 min read · ~3 pages · Grade level 15.6 · Accepted 2024-07-24 16:07:33
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-24-028917.txt ( ) — 216KB
- mira-20240724.xsd (EX-101.SCH) — 3KB
- mira-20240724_lab.xml (EX-101.LAB) — 33KB
- mira-20240724_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACEUTICALS, INC. Date: July 24, 2024 By: /s/ Erez Aminov Erez Aminov Chief Executive Officer